Lanreotide (Somatuline Depot) Dosage Calculator
Lanreotide is a synthetic octapeptide analog of somatostatin, marketed as Somatuline Depot.
60mcg · Monthly
Summary: Add 0mL BAC water to your 60mg vial. Draw to < 0.1 units on a U-100 syringe for a 60mcg dose. This vial will last 0 doses.
Cycle Planner
Lanreotide (Somatuline Depot) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~23-30 days (depot formulation)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Lanreotide (Somatuline Depot) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 60mg | Monthly |
| Moderate | 90mg | Monthly |
| Aggressive | 120mg | Monthly |
Note: Lanreotide is administered as a deep subcutaneous injection every 28 days, not weekly. The "Weekly" frequency is used as the closest valid option — actual dosing is once every 4 weeks (q28d). Available as a pre-filled syringe (Somatuline Depot) in 60mg, 90mg, and 120mg strengths. Dose selection depends on GH/IGF-1 levels for acromegaly or tumor grade for GEP-NETs. Do not mix or dilute — inject the full syringe at room temperature into the upper outer quadrant of the buttock.
About Lanreotide (Somatuline Depot)
Lanreotide is a synthetic octapeptide analog of somatostatin, marketed as Somatuline Depot. It binds primarily to somatostatin receptor subtypes 2 (SST2) and 5 (SST5), inhibiting growth hormone (GH) secretion, reducing IGF-1 levels, and exerting antiproliferative effects on neuroendocrine cells. FDA-approved since 2007 for acromegaly and since 2014 for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The depot formulation uses a supersaturated solution that forms a gel deposit at the injection site, providing sustained drug release over 28 days.